Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
KAI1 expression can be a predictor of stage A prostate cancer progression
Autore:
Tozawa, K; Akita, H; Kawai, N; Okamura, T; Sasaki, S; Hayashi, Y; Kohri, K;
Indirizzi:
Nagoya City Univ, Sch Med, Dept Urol, Nagoya, Aichi 467, Japan Nagoya CityUniv Nagoya Aichi Japan 467 pt Urol, Nagoya, Aichi 467, Japan Meijo Hosp, Dept Urol, Nagoya, Aichi, Japan Meijo Hosp Nagoya Aichi Japan eijo Hosp, Dept Urol, Nagoya, Aichi, Japan
Titolo Testata:
PROSTATE CANCER AND PROSTATIC DISEASES
fascicolo: 3, volume: 4, anno: 2001,
pagine: 150 - 153
SICI:
1365-7852(2001)4:3<150:KECBAP>2.0.ZU;2-X
Fonte:
ISI
Lingua:
ENG
Soggetto:
METASTASIS SUPPRESSOR GENE; ADENOCARCINOMA; PROGNOSIS; SURVIVAL; PROTEIN; GRADE;
Keywords:
prostate cancer; progression; KAI1 protein;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
17
Recensione:
Indirizzi per estratti:
Indirizzo: Tozawa, K Nagoya City Univ, Sch Med, Dept Urol, Nagoya, Aichi 467, Japan Nagoya City Univ Nagoya Aichi Japan 467 agoya, Aichi 467, Japan
Citazione:
K. Tozawa et al., "KAI1 expression can be a predictor of stage A prostate cancer progression", PROSTATE C, 4(3), 2001, pp. 150-153

Abstract

The disease progression and rate of cancer death were analyzed in 52 patients with stage A prostate cancer who underwent transurethral resection of the prostate (TURP) or retropubic subcapsular prostatectomy (SCP) between 1987 and 1998. We performed immunohistochemistry on 16 patients to determine the correlation between the expression of the tumor metastasis suppressor gene KAI1 and the subsequent progression of stage A prostate cancer. Nineteen and 33 of the patients had cancer at stage A1 and stage A2, respectively,and their subsequent courses were followed for an average of 53.7 months (24-134 months). Progression to clinical cancer was, found in six patients (one with stage A1, and five with stage A2). This progression was evident 40.8 months (5-80 months) after TURP or SCR Four (66.7%) of the patients diedof cancer progression (average 31 months) after prostatectomy. All four patients had stage A2, poorly differentiated adenocarcinoma, and had been followed with administration of diethylstilbestrol diphosphate (DES-P). The disease-free patients (n = 10) showed overexpression of KAI1 protein, compared to those with disease progression (n = 6). These results indicate that progression arose mainly in the patients with stage A2 cancer, and that poorly differentiated, focal and weak expression of KAI1 protein is highly associated with disease progression. It is suggested that patients in this groupshould be treated with immediate total androgen blockade, radiation, or radical prostatectomy after diagnosis.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 02/04/20 alle ore 13:01:38